Words by Isabel O’Brien
Bristol Myers Squibb (BMS) has announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, marking a significant leadership transition at the company. Gallman steps into the role following the retirement of Sandra Leung, who leaves after a 33-year career at the US-based firm.
A press release announcing the news said Gallman would bring a mix of legal, compliance and policy expertise to the post. Her career at BMS has spanned roles ranging from Head of Legal for Global Oncology to Chief Compliance and Ethics Officer, and most recently, Executive Vice President for Corporate Affairs. In these positions, she has been in charge of steering the company’s strategic communications, government relations, corporate social responsibility and patient advocacy efforts.
Gallman’s appointment comes at a key time for BMS, which recently committed to a $40bn, five-year investment in the US to strengthen its research and manufacturing capabilities. In her new role, she will oversee a broad portfolio including intellectual property, regulatory, litigation, corporate governance and global policy. This is particularly relevant as the pharma sector faces increasing regulatory scrutiny, pricing pressures and the challenge of sustaining innovation in a rapidly evolving landscape.
Christopher Boerner, Chair and CEO, BMS, praised Gallman’s “unique combination of legal, policy and communications expertise”, adding that her leadership will be crucial in advancing BMS’s mission to deliver medicines to patients with serious diseases. Gallman herself highlighted her commitment to upholding the company’s culture of integrity and fostering a policy environment that protects both innovation and patients.
Gallman’s predecessor, Sandra Leung, is widely credited with guiding BMS through significant industry shifts, including major acquisitions and the expansion of the company’s key portfolios. Leung’s legacy, as noted by Boerner, is one of resilience and steadfast dedication to patient-centric values.
The appointment of the new incumbent took effect on 6 May 2025.
